Solventum Corp Files 8-K on Officer/Director Changes

TL;DR

Solventum Corp (formerly 3M Health Care) filed an 8-K detailing changes in its leadership and compensation structure.

AI Summary

Solventum Corporation, formerly 3M Health Care Co, filed an 8-K on October 21, 2025, reporting events as of October 17, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Solventum Corporation is incorporated in Delaware and has its principal executive offices at 3M Center, Maplewood, Minnesota.

Why It Matters

This filing indicates significant corporate governance and executive changes within Solventum Corporation, which could impact its strategic direction and operational management.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding leadership and compensation, not indicating immediate financial distress or significant operational shifts.

Key Players & Entities

• Solventum Corporation (company) — Registrant
• 3M Health Care Co (company) — Former Company Name
• 3M Company (company) — Associated Company
• October 17, 2025 (date) — Date of earliest event reported
• October 21, 2025 (date) — Date of report
• Delaware (location) — State of incorporation
• Maplewood, Minnesota (location) — Address of Principal Executive Offices

FAQ

Filing Documents

• solv-20251017.htm (8-K) — 24KB
• 0001628280-25-045731.txt ( ) — 140KB
• solv-20251017.xsd (EX-101.SCH) — 2KB
• solv-20251017_lab.xml (EX-101.LAB) — 22KB
• solv-20251017_pre.xml (EX-101.PRE) — 13KB
• solv-20251017_htm.xml (XML) — 3KB

From the Filing

solv-20251017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2025 SOLVENTUM CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware File No. 001-41968 92-2008841 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East , Maplewood , Minnesota 55144 (Address of Principal Executive Offices) (Zip Code) (Registrant's Telephone Number, Including Area Code) ( 651 ) 733-1110 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $.01 Per Share SOLV New York Stock Exchange Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, Solventum Corporation (the "Company") announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company's MedSurg, Dental Solutions and Health Information Systems segments and will report directly to CEO Bryan Hanson. In connection with Ms. Knight's appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart the Company effective December 31, 2025. Upon execution and non-revocation of a general release of claims, Mr. Barry is entitled to receive severance benefits under the Solventum Executive Severance Plan (the "Severance Plan") and his outstanding equity awards will be treated in accordance with the applicable award agreements (as modified by the Severance Plan, if applicable). The Severance Plan and the Company's form of equity award agreements have previously been filed as exhibits to the Company's filings with the U.S. Securities and Exchange Commission. About Heather Knight Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sales across three business segments, as well as R&D, supply chain, and medical and regulatory affairs. Throughout her career, Ms. Knight has held numerous roles of increasing leadership in general management, global upstream and commercial capacities at companies including Medtronic plc, Covidien plc, Tyco Healthcare and Kendall, and she currently serves on the Board of Directors of Waters Corporation. Ms. Knight earned her bachelor's degree in Biological Sciences from the University of Buffalo and completed the Executive Sales Strategy and Management program from the University of Chicago Booth School of Management. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Wayde McMillan Wayde McMillan Executive Vice President and Chief Financial Officer Dated: October 21, 2025

View Full Filing

View this 8-K filing on SEC EDGAR